Ensifentrine

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the European Respiratory Society (“ERS”) International Congress 2024. The abstracts are available to conference participants on the ERS website and will be published in an upcoming issue of the peer reviewed publication, European Respiratory Journal. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. The therapy is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years. The analyses will summarize the efficacy and safety of Ohtuvayre in the subgroup of patients, including reduction in the rate of exacerbation, with or without chronic bronchitis and in European patients. Additionally, a pooled analysis of patient reported outcomes and the effect of Ohtuvayre on reducing cough and sputum will also be presented. “These analyses provide further support for Ohtuvayre’s potential to benefit a broad population of patients with COPD,” said Jadwiga Wedzicha, MD, Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UK. “The non-steroidal anti-inflammatory effects with this novel therapy are particularly beneficial and I am very excited about the impact of Ohtuvayre on COPD.” Details of Verona Pharma’s presentations and posters are listed below and linked to the ERS website: Oral presentation 2780: Ensifentrine improved lung function and reduced moderate/severe exacerbation rate and risk in patients with COPD regardless of chronic bronchitis historyParticipant: Jadwiga Wedzicha, MD, Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, UKSession 265: Airway diseases therapeutics: novel research studies Poster 2991: Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trialsParticipant: Alexander Mathioudakis, MD, NIHR Clinical Lecturer in Respiratory Medicine, University of Manchester, UKSession 300: New frontiers in chronic obstructive pulmonary disease treatment and management Poster 2995: Efficacy and safety of ensifentrine in European patients with moderate to severe COPD: pooled results from the ENHANCE trialsParticipant: Frits M.E. Franssen, MD, Head of the Department of Respiratory Medicine, Maastricht University Medical Center, The NetherlandsSession 300: New frontiers in chronic obstructive pulmonary disease treatment and management Poster 2997: Ensifentrine improved symptoms and reduced moderate/severe exacerbation rate and risk in patients with COPD and significant cough and sputumParticipant: Victor Kim, MD, Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, USSession 300: New frontiers in chronic obstructive pulmonary disease treatment and management For further information please contact: Verona Pharma plcTel: +1-844-341-9901Victoria Stewart, Senior Director of Investor Relations and CommunicationsIR@veronapharma.comArgot Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartners.comTen Bridge CommunicationsInternational / US Media EnquiriesTel: +1-312-523-5016tbcverona@tenbridgecommunications.comLeslie Humbel About Ohtuvayre (ensifentrine) Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD. About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre and future poster presentations and academic publications pertaining to Ohtuvayre. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the efficacy of Ohtuvayre compared to competing drugs and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) on August 8, 2024, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law.

一般而言，一些Biotech初创公司通常依赖风险投资而不依赖贷款。毕竟初创公司可能需要数年时间才能产生收入，而贷款这一行为虽然不会稀释股权，但是可能出现没钱还债的情况，对于一些情况堪忧的Biotech来说，这种行为无异于饮鸩止渴。 然而，随着近年来公共和私人股本投资的减少（尤其是受到美联储加息的影响），更多的Biotech初创公司转向了债务融资，而偏偏就有一些公司专门致力于生物技术方面的债务融资。本文将列举近年来出现的一些比较专注于Biotech放贷的公司。 Hercules Capital Hercules Capital，全称Hercules Technology Growth Capital, Inc.（股票代码HTGC），是一家专业金融公司，专注于为各种技术、生命科学以及可持续和可再生技术行业中的高增长、风险资本支持的公司提供优先担保贷款。 名字可以看到取自于希腊神话大力神赫拉克勒斯，这几年来这家公司在生物医药行业内提供了不菲的资金。 今年1月，Verona Pharma公司完成了一项债务融资，从牛津金融和Hercules Capital管理的基金中获得了高达4亿美元的资金。债务融资提供非稀释性资本和进一步的财务灵活性，以支持维罗纳制药的持续增长，包括ensifentrine的商业化。 今年3月19日，该公司为蓝鸟生物提供了总额约1.75亿美元的贷款，这笔贷款将用于支持蓝鸟生物的镰状细胞病基因疗法Lyfgenia的上市活动，并延长公司的现金流跑道。这笔贷款为期五年，分为几笔发放，其中包括第一笔7500万美元的贷款已在交易完成后提取，另外几笔贷款将在实现某些商业里程碑后提取。 今年4月30日，该公司为SynOx Therapeutics提供了3500万美元贷款，用于推进CSF-1(R)单抗——埃马妥珠单抗（emactuzumab）的开发和商业化。这笔交易增强了SynOx的资产负债表，有助于其推进emactuzumab的III期研究TANGENT。 今年5月16日，为了首款TCR-T上市产品的推出，现金紧张的TCR-T先驱Adaptimmune与风投公司Hercules Capital签订了一笔总额1.25亿美元、为期五年的定期贷款协议。该笔贷款分成五期，第一笔（2500万美元）在交易签订时立即到账，第二笔2500万美元在产品获批上市后发放。另外三期（7500万美元）在Adaptimmune符合某些条件后才能得到。 Pharmakon Advisors Pharmakon Advisors是生物制药信贷基金的投资管理公司。成立于2009年的Pharmakon已经筹集了49亿美元，主要通过五只私募基金和一只公开上市的英国信托基金。 今年4月23日，眼科治疗公司Tarsus Pharmaceuticals从Pharmakon Advisors，LP的相关基金获得2亿美元信贷，Tarsus通过Pharmakon的2亿美元非稀释性融资加强了财务状况，并对现有债务进行了再融资 今年5月2日Novocure与Pharmakon Advisors，LP管理的基金达成一项新的五年期高达4亿美元的承诺优先担保信贷安排。承诺资本将分四批提供给Novocure，每批1亿美元。所得款项将用于支付Novocure在非小细胞肺癌领域的预期上市所产生的营运资金需求，并在到期时结算Novocure的可转换票据。 黑石 黑石集团是企业需要钱时候的另一个选择，尤其是对于需要大笔资金的公司。黑石集团就拥有生命科学和信贷部门，一些生命科学方面相关的业务可能会被转交到信贷部门共同完成。 开发罕见病PTC Therapeutics在2022年10月时，获得了黑石两个部门提供的总额10亿美元贷款。 黑石生命科学和黑石信贷管理的基金将为PTC提供5亿美元的初始资本，以及后续5亿的潜在信贷额度或其他投资资本，以支持该公司业务发展机会，取决于黑石和PTC之间的相互协议。 总结 总的来说，利用信贷进行债务融资是非常有风险的，但在大环境下又不得不去这样做，之前上市了首款前列腺癌症疫苗Provenge的Dendreon公司正是因为公司欠下了6亿美元债务，Provenge销售额入不敷出而导致破产的。 参考来源： https://www.biospace.com/business/symbiotic-capital-launches-with-more-than-600m-to-provide-life-science-loans